Abstract 【Objective】To investigate the expression of heat shock protein 90(HSP90) in lung squamous cell carcinoma and analyze the relationship between its expression and clinicopathological characteristics and prognosis. 【Methods】 The cancer tissues of 159 lung squamous cell carcinoma(SCC) patients with complete follow-up data and 53 non-cancer control lung tissues(Non-CLT), who were selected from the thoracic surgery of the Second Xiangya Hospital of Central South University between 2003 and 2013, were retrospectively evaluated. High-throughput tissue microarray(TMA) were constructed and the expression of HSP90 were detected by immunohistochemistry(IHC). Kaplan-Meier univariate and Cox multivariate hazard regression analysis were performed to assess the prognosis of patients with lung SCC. 【Results】 Compared with Non-CLT, the positive expression rate of HSP90 in lung SCC tissue was significantly higher(P<0.05); and the expression level of HSP90 in clinical stage Ⅲ patients was higher than that in clinical stage Ⅰ-Ⅱ patients(P=0.010). The expression level of HSP90 in patients with lymph node metastasis was higher than that in patients without lymph node metastasis(P=0.016). The overall survival rate of patients with lung squamous cell carcinoma with high expression of HSP90 was significantly lower than that of patients with low expression of HSP90(P=0.002). Cox multivariate risk regression analysis found that patients with lung SCC with high expression of HSP90 had a worse prognosis than low expression of HSP90(P=0.042). 【Conclusion】 In addition to the clinical stage and pathological grade of the tumor, the high expression of HSP90 can be used as an independent molecular marker for evaluating the poor prognosis of patients with surgically removed lung SCC.
[1] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424. [2] ZHOU M, WANG H, ZENG X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017:a systematic analysis for the global burden of disease study 2017[J].Lancet,2019,394(10204):1145-1158. [3] DUMA N, SANTANA-DAVILA R, MOLINA J R. Non-small cell lung cancer:epidemiology, screening, diagnosis, and treatment[J].Mayo Clin Proc,2019,94(8):1623-1640. [4] OSMANI L, ASKIN F, GABRIELSON E, et al. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma(NSCLC):Moving from targeted therapy to immunotherapy[J].Semin Cancer Biol,2018,52(Pt 1):103-109. [5] YUN C W, KIM H J, LIM J H, et al. Heat shock proteins:Agents of cancer development and therapeutic targets in anti-cancer therapy[J].Cells,2020,9(1):60. [6] HOTER A, EL-SABBAN M, NAIM H. The HSP90 family:structure, regulation, function, and implications in health and disease[J].Int J Mol Sci,2018,19(9):2560. [7] FENG J, XIE G, ZHAN Y, et al. Elevated HSP90 associates with expression of HIF-1 alpha and p-AKT and is predictive of poor prognosis in nasopharyngeal carcinoma[J].Histopathology,2019,75(2):202-212. [8] ZHANG S, GUO S, LI Z, et al. High expression of HSP90 is associated with poor prognosis in patients with colorectal cancer[J].Peer J,2019,7:e7946. [9] 罗小怀, 桂普国, 杜一鸿. HSP90α联合肿瘤标志物水平检测对肝癌患者预后的评估价值[J].实用癌症杂志, 2019,34(9):1405-1408. [10] 李东航, 姚颐, 耿庆. 中国临床肿瘤学会肺癌诊疗指南(2018版)更新解读[J].临床外科杂志, 2019,27(1):36-39. [11] DETTERBECK F C, BOFFA D J, KIM A W, et al. The eighth edition lung cancer stage classification[J].Chest,2017,151(1):193-203. [12] FAN S, MA J, ZHOU J, et al. Differential expression of Epstein-Barr virus-encoded RNA and several tumor-related genes in various types of nasopharyngeal epithelial lesions and nasopharyngeal carcinoma using tissue microarray analysis[J].Hum Pathol,2006,37(5):593-605. [13] TANG Y, YANG Y, LUO J, et al. Overexpression of HSP10 correlates with HSP60 and Mcl-1 levels and predicts poor prognosis in non-small cell lung cancer patients[J].Cancer Biomarkers,2021,30(1):85-94. [14] CAO M, CHEN W. Epidemiology of lung cancer in China[J].Thorac Cancer,2019,10(1):3-7. [15] JAFARI A, REZAEI-TAVIRANI M, FARHADIHOSSEINABADI B, et al. HSP90 and co-chaperones:impact on tumor progression and prospects for molecular-targeted cancer therapy[J].Cancer Invest,2020,38(5):310-328. [16] LIN T, QIU Y, PENG W, et al. Heat shock protein 90 family isoforms as prognostic biomarkers and their correlations with immune infiltration in breast cancer[J].Biomed Res Int,2020,2020:2148253. [17] 龚永谦, 程爱兰, 刘洁. 鼻咽癌组织EGFR、HSP90A和组织蛋白酶D表达水平及其与肿瘤侵袭转移的关系分析[J].重庆医学, 2018,47(16):2158-2161. [18] 刘俊雅.Hsp90在胰腺癌组织中表达升高及其临床病理意义[J].基础医学与临床, 2018,38(4):497-501. [19] 陈涛, 杜维. 非小细胞肺癌患者热休克蛋白90α、凋亡促进因子Bax、凋亡抑制因子Bcl-2表达水平变化及与病理学特征的相关性[J].中国医学工程, 2019,27(8):9-13. [20] 牛永亮, 李小波, 王波, 等. 非小细胞肺癌组织中Hsp90β和survivin的表达及其临床意义[J].临床肺科杂志, 2018,23(4):598-603. [21] NAGARAJU G P, ZAKKA K M, LANDRY J C, et al. Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer[J].Int J Cancer,2019,145(6):1529-1537. [22] ZHANG P, LIU X, LI M, et al. AT-533, a novel Hsp90 inhibitor, inhibits breast cancer growth and HIF-1α/VEGF/VEGFR-2-mediated angiogenesis in vitro and in vivo[J].Biochem Pharmacol,2020,172:113771. [23] CHO T, KIM J Y, KIM Y, et al. C-terminal HSP90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition[J].Cancer Letters,2019,447:141-153. [24] PAK M G, KOH H J, ROH M S. Clinicopathologic significance of TRAP1 expression in colorectal cancer:a large scale study of human colorectal adenocarcinoma tissues[J].Diagn Pathol,2017,12(1):6. [25] KRYEZIU K, BRUUN J, GUREN T K, et al. Combination therapies with HSP90 inhibitors against colorectal cancer[J].Biochim Biophys Acta Rev Cancer,2019,1871(2):240-247. [26] 张钟元, 阎爱侠. Hsp90抑制剂的研究进展[J].中国医药生物技术, 2021,16(1):41-50. [27] LI L, CHEN N N, YOU Q D, et al. An updated patent review of anticancer Hsp90 inhibitors(2013-present)[J].Expert Opin Ther Pat,2021,31(1):67-80.
[1]
. [J]. JOURNAL OF CLINICAL RESEARCH, 2021, 38(9): 1410-1412.
2021, Vol. 38 
